NCT04620382View on ClinicalTrials.gov

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Neurogenic Orthostatic HypotensionAutonomic FailurePure Autonomic FailureMultiple System AtrophyParkinson Disease
Interventions
DRUG

Midodrine

Midodrine 5-10 mg, single oral dose

DRUG

Placebo pill

single oral dose

DEVICE

Abdominal compression

abdominal compression up to 40 mmHg during head-up tilt

DEVICE

sham compression

Sham abdominal compression during head-up tilt

Trial Locations (1)

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Vanderbilt University Medical Center

OTHER